Equities

Wuhan YZY Biopharma Co Ltd

Wuhan YZY Biopharma Co Ltd

Actions
  • Price (HKD)4.99
  • Today's Change0.00 / 0.00%
  • Shares traded21.00k
  • 1 Year change-43.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments197201103
Total Receivables, Net160.340.33
Total Inventory5.77118.91
Prepaid expenses312013
Other current assets, total0.697.221.17
Total current assets250239126
Property, plant & equipment, net515560
Goodwill, net------
Intangibles, net------
Long term investments0.490.540.58
Note receivable - long term0.518.6714
Other long term assets------
Total assets302303200
LIABILITIES
Accounts payable2.953.215.38
Accrued expenses362613
Notes payable/short-term debt907728
Current portion long-term debt/capital leases0.460.170.40
Other current liabilities, total454110
Total current liabilities17414757
Total long term debt0.1500.08
Total debt907728
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities17414757
SHAREHOLDERS EQUITY
Common stock1941820
Additional paid-in capital345193165
Retained earnings (accumulated deficit)(411)(220)(22)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity128156143
Total liabilities & shareholders' equity302303200
Total common shares outstanding194193193
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.